Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing the new Tapestri Solution for Solid Tumor Oncology Research. Learn More
X
publication

Polyclonal Heterogeneity: The New Norm for Secondary Clinical Resistance to Targeted Monotherapy in Relapsed Leukemia?


Wei, A.H. et al.
Cancer Discovery (2019)
Abstract

In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias..



Authors

Wei, A.H., Roberts, A.W.



VIEW

publication
Single cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia
Troy T. Robinson
publication
The genomic landscape of pediatric acute lymphoblastic leukemia
Samuel W. Brady
Nature Genetics
publication
Detection of early seeding of Richter transformation in chronic lymphocytic leukemia
Ferran Nadeu
Nature Medicine (2022)
publication
Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation
Bowman RL
BioRxiv (2022)
REQUEST QUOTE